{"id":32573,"date":"2026-04-17T07:48:41","date_gmt":"2026-04-17T07:48:41","guid":{"rendered":"https:\/\/rhepa.se\/?page_id=32573"},"modified":"2026-05-19T07:25:09","modified_gmt":"2026-05-19T07:25:09","slug":"elementor-32573","status":"publish","type":"page","link":"https:\/\/rhepa.se\/en\/elementor-32573\/","title":{"rendered":"Scientific Advisory Board - Next Generation"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Scientific Advisory Board - Next Generation<\/i><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Our Scientific Advisory Board consists of eminent medical experts, professors and doctors with deep specialist knowledge within different medical fields. The board members each have their own broad global network of medical experts. In total, hundereds of experts and researchers at scientific institutions are included around the world in this extended network. This gives the portfolio managers opportunity to gain deeper insights and understanding, and to access the latest research.\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
G\u00f6ran Ando\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Doctor of Medicine\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

G\u00f6ran Ando is a medical doctor and has more than 40 years of leadership in the biotech and pharmaceutical industry, including 13 years as vice-chairman and chairman of Novo Nordisk AS. He joined the industry with Pfizer and has subsequently spent most time with Glaxo (now GSK) as medical director advancing to development director and finally R&D Director. In 1995 he joined Pharmacia as Executive Vice President and Deputy CEO heading R&D, manufacturing, IT, BD and M&A. When Pharmacia was sold in 2003, he was appointed CEO of Celltech Group in the UK until UCB acquired the company. G\u00f6ran is a qualified medical doctor and a founding fellow of the American College of Rheumatology. He was awarded an honorary doctors degree by Karolinska Institute in 2002.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Mia von Euler<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
MD, PhD<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
Mia von Euler is a medical doctor and Professor of neurology with over 25 years of experience. She currently serves as President at Sophiahemmet University College. Mia obtained her MD and PhD at Karolinska Institutet and recently held position as Dean and Professor at Medical Faculty at \u00d6rebro University. Her research spans multiple areas including stroke, epilepsy, neuropharmacology and gender differences. She also serves as Chair of the Swedish Research Council\u2019s Committee for Clinical Therapy Research\u00a0and also of the\u00a0Swedish Stroke Registry (Riksstroke).\u00a0<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Rickard Lindblom<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
MD, PhD<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Rickard Lindblom is a medical doctor and senior consultant in cardiothoracic surgery at Uppsala University Hospital. He has extensive experience in cardiovascular surgery and both clinical and preclinical research. Dr Lindblom has played a key role in advancing surgical techniques and patient outcomes in the field of cardiothoracic surgery. He earned his medical degree and PhD from Karolinska Institutet in 2008 and 2013 respectively. Since 2019, he is also appointed associate professor at Uppsala University where he contributes as a lecturer and mentor to medical students and residents.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Rickard Sandberg<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
PhD\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Rickard Sandberg is a professor of molecular genetics at Karolinska Institutet and a leading researcher in gene regulation and single-cell genomics. He earned his PhD at Karolinska Institutet and conducted postdoctoral research at the Massachusetts Institute of Technology before returning to Sweden to establish his own research group. Rickard\u2019s work has been instrumental in developing single-cell RNA sequencing methods. He has received numerous awards and honors, including election to EMBO and membership in the Nobel Assembly at Karolinska Institutet, as well as the Torsten S\u00f6derberg Academy Professorship in Medicine.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Carl\u2011Harald Janson<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
MD, PhD\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Carl Harald Janson is a medical doctor and investor with over 25 years of experience in biotechnology, pharmaceuticals, and asset management. Carl Harald started his career at Astra AB holding positions both in clinical development and pre-clinical development. Carl Harald later transitioned into the financial sector, holding senior investment roles at Carnegie Investment Bank and Karolinska Development, where he served as Vice President of Portfolio Management and CEO portfolio companies developing targeted cancer therapies. Most recently Carl Harald was the lead investment manager of the International Biotechnology Trust in London. Carl Harald is a Certified European Financial Analyst (CEFA) and holds an MD and PhD from Karolinska Institutet.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Vetenskapligt r\u00e5d – Next Generation V\u00e5rt vetenskapliga r\u00e5d best\u00e5r av ledande professorer, l\u00e4kare, forskare och experter inom olika medicinska omr\u00e5den. Ledam\u00f6terna har i sin tur ett gediget n\u00e4tverk inom sina respektive delsektorer. Totalt ing\u00e5r hundratals forskare och experter p\u00e5 vetenskapliga institutioner runt om i v\u00e4rlden. Detta ger f\u00f6rvaltarna m\u00f6jlighet till djupare insikter, samt tillg\u00e5ng till […]<\/p>\n","protected":false},"author":9,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-32573","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/pages\/32573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/comments?post=32573"}],"version-history":[{"count":33,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/pages\/32573\/revisions"}],"predecessor-version":[{"id":33093,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/pages\/32573\/revisions\/33093"}],"wp:attachment":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/media?parent=32573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}